Paper Details

  1. Home
  2. Paper Details

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).

Author: AbraoMauricio S, Arjona FerreiraJuan C, As-SanieSawsan, BeckerChristian M, BrownEric, DynowskiKrzysztof, GiudiceLinda C, JohnsonNeil P, LesseyBruce A, LiYulan, MathurVandana, WagmanRachel B, WarsiQurratul Ann, WilkKrzysztof

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Relugolix combination therapy, an oral gonadotropin-releasing hormone receptor antagonist, significantly improved endometriosis-associated pain and was well-tolerated. Two phase 3, randomized, double-blind, placebo-controlled trials showed that relugolix combination therapy led to a high responder rate for dysmenorrhea and non-menstrual pelvic pain. The most common adverse events were headache, nasopharyngitis, and hot flushes, with no deaths reported.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was evaluated for treatment of endometriosis-associated pain. METH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(22)00622-5

データ提供：米国国立医学図書館（NLM）

Relugolix Combination Therapy: A New Hope for Endometriosis-Associated Pain

We're exploring the landscape of endometriosis, a painful condition that affects many women. This study investigates the efficacy of relugolix combination therapy in treating endometriosis-associated pain. It's like finding a new oasis in the desert of pain—a potential remedy for a debilitating condition.

A Breakthrough in Endometriosis Treatment

The study, a comprehensive evaluation of relugolix combination therapy, found that this oral therapy significantly improved endometriosis-associated pain and was well-tolerated. The authors observed significant reductions in both dysmenorrhea and non-menstrual pelvic pain, offering a promising new treatment option for women with endometriosis. It's like finding a source of healing water in a parched desert—a transformative experience that can bring relief from chronic pain.

A New Era in Endometriosis Management

This study highlights the potential of relugolix combination therapy to transform the management of endometriosis. The findings pave the way for a new era in endometriosis treatment, offering hope for women who have long sought effective and tolerable therapies. It's like embarking on a new journey through a desert landscape—one filled with promise and the potential for a brighter future.

Dr.Camel's Conclusion

This research is a beacon of hope in the fight against endometriosis-associated pain. Relugolix combination therapy offers a potential solution to a debilitating condition, offering women a chance for a better quality of life. Just as a desert traveler seeks a haven from the harsh elements, women with endometriosis can find solace and relief through this promising new therapy.

Date :
  1. Date Completed 2022-06-21
  2. Date Revised 2022-10-24
Further Info :

Pubmed ID

35717987

DOI: Digital Object Identifier

10.1016/S0140-6736(22)00622-5

Related Literature

Article Analysis
・Effective treatment of endometriosis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.